PartnerRe Ltd. Declares Quarterly Dividend of $0.70 Per Ordinary Share

PEMBROKE, Bermuda--(BUSINESS WIRE)-- PartnerRe Ltd. (NYSE: PRE) today announced that its Board of Directors has declared a dividend of $0.70 per common share.

The dividend will be payable on September 1, 2015, to common shareholders of record on August 7, 2015.

____________________________________________________

PartnerRe Ltd. is a leading global reinsurer, providing multi-line reinsurance to insurance companies. The Company, through its wholly owned subsidiaries, also offers capital markets products that include weather and credit protection to financial, industrial and service companies. Risks reinsured include property, casualty, motor, agriculture, aviation/space, catastrophe, credit/surety, engineering, energy, marine, specialty property, specialty casualty, multiline and other lines in its Non-life operations, mortality, longevity and accident and health in its Life and Health operations, and alternative risk products. For the year ended December 31, 2014, total revenues were $6.5 billion. At March 31, 2015, total assets were $22.5 billion, total capital was $8.0 billion and total shareholders’ equity attributable to PartnerRe was $7.2 billion.

PartnerRe on the Internet: www.partnerre.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150727005605/en/

PartnerRe Ltd.
Investors:
Robin Sidders, 441-292-0888
or
Media:
Celia Powell, 441-292-0888
or
Sard Verbinnen & Co
Drew Brown/Robin Weinberg
212-687-8080

Source: PartnerRe Ltd.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
• Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
• Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026